MapLight Therapeutics (MPLT) Depreciation & Amortization (CF) (2024 - 2025)

MapLight Therapeutics (MPLT) reported Depreciation & Amortization (CF) of $200000.0 for Q4 2025, little changed on a YoY basis from $201000.0 in Q4 2024, and up 100.0% sequentially from $100000.0 in Q3 2025.

MapLight Therapeutics (MPLT) Depreciation & Amortization (CF) (2024 - 2025) Analysis & Trends

MapLight Therapeutics (MPLT) has 2 years of Depreciation & Amortization (CF) data on file, last reported at $200000.0 in Q4 2025.

  • For the quarter ending Q4 2025, Depreciation & Amortization (CF) changed 0.5% year-over-year to $200000.0; the trailing twelve-month figure through Dec 2025 stood at $701000.0 (changed N/A YoY), and the FY2025 full-year result was $600000.0, down 14.41% from the prior year.
  • Depreciation & Amortization (CF) rose to $200000.0 in Q4 2025, from $100000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $201000.0 in Q4 2024 to a low of $100000.0 in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Depreciation & Amortization (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 196,658.72
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 41.14 Mn
4 NuCana 279.75 Bn 279.75 Bn - 91,781.47
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 55.90 Mn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 123.20 Mn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - 2.20 Mn
10 MapLight Therapeutics 305.82 Mn 305.82 Mn - 200,000.00

Historic Data

Download Data
DateValue
Dec 31, 2025 200,000.00
Dec 31, 2025 200,000.00
Sep 30, 2025 100,000.00
Sep 30, 2025 100,000.00
Dec 31, 2024 201,000.00
Dec 31, 2024 201,000.00
Sep 30, 2024 200,000.00
Sep 30, 2024 200,000.00